Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01170702 · ClinicalTrials.gov registry record · Phase 4
Transverse Abdominis Plane (TAP) Block After Cesarean Delivery
A Phase 4 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT01170702 is a Phase 4 study that has completed, run by Northwestern University. The registered enrollment target is 120 participants.
The verdict
NCT01170702, a Phase 4 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
Since there have been no published dose-response studies investigating the effective analgesic dose of ropivacaine for use in a TAP block for post-Cesarean delivery analgesia, the investigators propose a study primarily examining the effect on 24 hour post-Cesarean delivery opioid consumption of using either a placebo, 0.25% ropivacaine, 0.5% ropivacaine, or 0.75% ropivacaine for TAP blocks.
Interventions
- DRUG 0.9% Normal Saline
- DRUG 0.2% Ropivacaine
- DRUG 0.5% Ropivacaine
- DRUG 0.75% Ropivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2010-01 |
| Est. Completion | 2017-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01170702
The ClinicalTrials.gov registry entry for NCT01170702 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 0.9% Normal Saline is the first listed.
NCT01170702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01170702 about?
NCT01170702 is a clinical study titled "Transverse Abdominis Plane (TAP) Block After Cesarean Delivery". Since there have been no published dose-response studies investigating the effective analgesic dose of ropivacaine for use in a TAP block for post-Cesarean delivery analgesia, the investigators propose a study primarily examining the effect on 24 hour post-Cesarean delivery opioid consumption of usi...
What is the current status of trial NCT01170702?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2010-01. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01170702?
The interventions under investigation include: 0.9% Normal Saline (DRUG), 0.2% Ropivacaine (DRUG), 0.5% Ropivacaine (DRUG), 0.75% Ropivacaine (DRUG).
Who is sponsoring clinical trial NCT01170702?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.